OCD

References

Barrett PM, Dadds MR, Rapee RM. Family treatment of childhood anxiety: a controlled study. J Consult Clin Psychol 1996; 64: 333–342.

Berk M, Koopowitz LF, Szabo CP. Antidepressant induced mania in obsessive–compulsive disorder. Eur Neuropsychopharmacol 1996; 6: 9–11.

Castle DJ, Deale A, Marks IM, Cutts F, Chadhoury Y, Steward A. Obsessive–compulsive disorder: prediction of outcome from behavioural psychotherapy. Acta Psychiatr Scand 1994; 89: 393–398.

Chouinard G, Goodman W, Greist J et al. Results of a double-blind placebo-controlled trial of a new serotonin reuptake inhibitor, sertraline, in the treatment of obsessive–compulsive disorder. Psychopharmacol Bull 1990; 26: 279–284.

Coryell W, Endicott J, Winokur J. Anxiety syndromes as epiphenomena of primary major depression: outcome and familial psychopathology. Am J Psychiatry 1992; 149: 100–107.

Cottraux JA, Bouvard M, Claustrat B, Jeunet C. Abnormal dexamethasone suppression in primary obsessive–compulsive patients: a confirmatory report. Psychiatry Res 1984; 13: 157–165.

Deakin, JFW. Does selectivity matter? Int Clin Psychopharmacol 1996; 11 (Suppl 1): 13–17.

de Haan E, van Oppen P, van Balkom AJLM, Spinhoven P, Hoogduin KAL, Van Dyck R. Prediction of outcome and early versus late improvement in OCD patients treated with cognitive behaviour therapy and pharmacotherapy. Acta Psychiatr Scand 1997; 96: 354–361.

den Boer JA. Psychopharmacology of comorbid obsessive–compulsive disorder and depression. J Clin Psychiatry 1997; 58 (Suppl 8): 17–19.

DeVaugh-Geiss J, Katz R, Landau P. Clinical predictors of treatment response in obsessive–compulsive disorder: exploratory analyses from multicentre trials of clomipramine. Psychopharmacol Bull 1990; 26: 54–59.

DeVaugh-Geiss J, Katz R, Landau P et al. Clomipramine in the treatment of patients with obsessive–compulsive disorder: the clomipramine collaborative study group. Arch Gen Psychiatry 1991; 48: 730–738.

Fawcett J. The detection and consequences of anxiety in clinical depression. J Clin Psychiatry 1997; 58 (Suppl 8): 35–40.

Fernandez-Cordoba E, Lopez-Ibor Aliño J. La monoclomipramina en enfermos psiquiatricos resistentes a ostros tratamientos. Acta Luso-Esp Neurol Psiquiatr Cienc Afines 1967; 26: 119–147.

Flament MF, Bisserbe JC. Pharmacologic treatment of obsessive–compulsive disorder: comparative studies. J Clin Psychiatry 1997; 58 (Suppl 12): 18–22.

Fontaine R, Chouinard G. Fluoxetine in the treatment of obsessive–compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 1986; 9: 605–608.

Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive–compulsive disorder: a double-blind comparison with placebo. Arch Gen Psychiatry 1989; 46: 36–44.

Goodman WK, Price LH, Delgado PL et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive–compulsive disorder: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990; 47: 577–585.

Greist JH, Chouinard G, DuBoff E et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive–compulsive disorder. Arch Gen Psychiatry 1995a; 52: 289–295.

Greist JH, Jefferson JW, Kobak KA, Katzelnik DJ, Serlin RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive–compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995b; 52: 53–60.

Greist JH, Jefferson JW, Kobak KA et al. A one-year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive–compulsive disorder. Int Clin Psychopharmacol 1995c; 10: 57–65.

Greist JH, Jenike MA, Robinson D et al. Efficacy of fluvoxamine in obsessive–compulsive disorder: results of a multicentre, double-blind placebo-controlled trial. Eur J Clin Res 1995d; 7: 195–204.

Gunasekara NS, Noble S, Benfield P. Paroxetine: an update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. CNS Drugs 1998; 55: 85–120.

Hollander E. Obsessive–compulsive disorder: the hidden epidemic. J Clin Psychiatry 1997;
58 (Suppl 12): 3–6.

Hollander E, DeCaria CM, Nitescu A et al. Serotonergic function in obsessive–compulsive
disorder. Arch Gen Psychiatry 1992; 49: 21–28.

Hollander E, Stein DJ, Broatch J et al. A pharmaco-economic and quality of life study of
OCD. In: Scientific abstracts of the 34th annual meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, 11–15 December 1995.

Hollander E, Greenwald S, Neville D, Johnson J, Hornig CD, Weissman MM.
Uncomplicated and comorbid obsessive–compulsive disorder in an epidemiologic sample. Depress Anxiety 1996a; 4: 111–119.

Hollander E, Kwon JH, Stein DJ et al. Obsessive–compulsive disorder and spectrum
disorders: overview and quality of life issues. J Clin Psychiatry 1996b; 57 (Suppl 8): 3–6.

Insel TR, Kalin NH, Guttmacher LB, Cohen RM, Murphy DL. The dexamethasone suppression test in patients with primary obsessive–compulsive disorder. Psychiatry Res 1982; 6: 153–160.

Insel TR, Murphy DL, Cohen RM et al. Obsessive–compulsive disorder: a double-blind
trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983; 40: 605–612.

Jenike MA, Hyman S, Baer L et al. A controlled trial of fluvoxamine in obsessive–compulsive disorder: implication for a serotonergic theory. Am J Psychiatry 1990; 147: 1209–1215.

Karno M, Golding KM, Sorenson SB et al. The epidemiology of obsessive–compulsive disorder in five US communities. Arch Gen Psychiatry 1988; 45: 1094–1099.

Koponen H, Lepola U, Leinonen E, Jokinen R, Penttinen J, Turtonen J. Citalopram in the treatment of obsessive–compulsive disorder: an open pilot study. Acta Psychiatr Scand 1997; 96: 343–346.

Kramer H, Sprenger J. Malleus maleficarum. London: Pushkin Press; 1951.

Lane RM. Pharmacokinetic drug interaction potential of SSRIs. Int Clin Psychopharmacol 1996; 11 (Suppl 5): 31–61.

Leonard HL. New developments in the treatment of obsessive–compulsive disorder. J Clin Psychiatry 1997; 58 (Suppl 14): 39–45.

Leonard HL, Swedo SE, Rapaport JL et al. Treatment of obsessive–compulsive disorder with clomipramine and desipramine in children and adolescents: a double-blind crossover comparison. Arch Gen Psychiatry 1989; 46: 1088–1092.

Liebowitz MR, Hollander E, Schneier FR et al. Fluoxetine treatment of obsessive–compulsive disorder: an open clinical trial. J Clin Psychopharmacol 1989; 9: 423–427.

McDougle CJ. Update of pharmacologic management of OCD: agents and augmentation. J Clin Psychiatry 1997; 58 (Suppl 12): 11–17.

McDougle CJ, Goodman WK, Leckman JF et al. Haloperidol addition in fluvoxamine-refractory obsessive–compulsive disorder: a double-blind placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994; 51: 302–308.

McDougle CJ, Potenza MN. Atypical neuroleptics in obsessive–compulsive disorder. Int Drug Ther Newsletter 1998; 33: 21–24.

Murphy DL, Zohar J, Benkelfat C et al. Obsessive–compulsive disorder as a 5?HT subsystem-related behavioural disorder. Br J Psychiatry 1989; 155 (Suppl 8): 15–24.

Murray CJL, Lopez AD, eds. Global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Vol 1. Harvard: World Health Organisation, 1996.

Pato MT, Zohar-Kadouch R, Zohar J et al. Return of symptoms after discontinuation of clomipramine in patients with obsessive–compulsive disorder. Am J Psychiatry 1988; 145: 1521–1525.

Pato MT, Murphy DL, DeVane CL. Sustained plasma concentrations of fluoxetine and/or norfluoxetine for eight weeks after fluoxetine discontinuation. J Clin Psychopharmacol 1991; 11: 224–225.

Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive–compulsive disorder: a meta-analytic review. Br J Psychiatry 1995; 166: 464–443.

Pigott TA, Pato MT, Bernstein SE et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive–compulsive disorder. Arch Gen Psychiatry 1990; 47: 926–932.

Rasmussen SA, Eisen JL. Treatment strategies for chronic and refractory obsessive–compulsive disorder. J Clin Psychiatry 1997; 58 (Suppl 13): 9–13.

Ravizza L, Barzega G, Bellino S et al. Drug treatment of obsessive–compulsive disorder: long-term trial with clomipramine and selective serotonin reuptake inhibitors. Psychopharmacol Bull 1996; 32: 167–173.

Sasson Y, Zohar J, Chopra M, Lustig M, Iancu I, Hendler T. Epidemiology of obsessive–compulsive disorder: a world review. J Clin Psychiatry 1997; 58 (Suppl 12): 7–10.

Simeon JG, Thatte S, Wiggins D. Treatment of adolescent obsessive–compulsive disorder with a clomipramine–fluoxetine combination. Psychopharmacol Bull 1990; 26: 285–290.

Stein DJ, Simeon D, Cohen LJ, Hollander E. Trichotillomania and obsessive–compulsive disorder. J Clin Psychiatry 1995a; 56S: 28–34.

Stein DJ, Spandaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive–compulsive disorder. Int Clin Psychopharmacol 1995b; 10: 11–18.

Stein DJ, Mullen L, Islam MN, Cohen L, DeCaria CM, Hollander E. Compulsive and impulsive symptomatology in trichotillomania. Psychopathology 1995c; 28: 208–213.

Stein DJ, Bouwer C, van Heerden B. Pica and the obsessive–compulsive disorder spectrum disorders. S Afr Med J 1996; 86 (Suppl 12): 1586–1592.

Stein DJ, Le Roux L, Bouwer C, Van Heerden B. Is olfactory reference syndrome an obsessive–compulsive spectrum disorder? Two cases and a discussion. J Neuropsychiatry Clin Neurosci 1998; 10: 96–99.

Stein DJ, Hollander E. Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J Clin Psychiatry 1992; 53: 123–126.

Stein DJ, Hollander E. Serotonin specific re-uptake inhibitors in obsessive–compulsive disorder and related disorders. In: Feighner JP, Boyer WF, eds. Selective serotonin reuptake inhibitors. 2nd edn. Wiley: Chichester, 1996: 135–153.

Stekettee G, Shapiro LJ. Predicting behavioural outcome for agoraphobia and obsessive–compulsive disorder. Clin Psychol Rev 1995; 15: 317–346.

Swedo SE. Sydenham’s chorea: a model for childhood auto-immune neuropsychiatric disorders. JAMA 1994; 272: 1788–1791.

Swedo SE, Rapoport JL, Leonard H et al. Obsessive–compulsive disorder in children and adolescents: clinical phenomenology of 70 consecutive cases. Arch Gen Psychiatry 1989; 46: 335–341.

Tamini RR, Mavissakalian MR, Jones V, Olson S. Clomipramine versus fluvoxamine in obsessive–compulsive disorder. Ann Clin Psychiatry 1991; 3: 275–279.

Thoren P, Asberg M, Bertilsson L, Mellstrom B, Sjoqvist F, Traskman L. Clomipramine treatment of obsessive–compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry 1980; 37: 1289–1294.

Tollefson GD, Rampey AH, Potvin JH et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive–compulsive disorder. Arch Gen Psychiatry 1994; 51: 559–567.

Vallejo J, Olivares J, Marcos T et al. Clomipramine versus phenelzine in obsessive–compulsive disorder: a controlled clinical trial. Br J Psychiatry 1992; 161: 665–670.

Wheadon DE, Bushnell WD, Steiner M. A fixed dose study of 20, 40 or 60 mg paroxetine in the treatment of obsessive–compulsive disorder. Poster presented at the 33rd Annual Meeting of the ACN, Puerto Rico, December, 1993.

Zohar J, Insel TR. Obsessive–compulsive disorder: psychobiological approaches to diagnosis, treatment and pathophysiology. Biol Psychiatry 1987; 22: 667–687.

Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL. Serotonergic responsivity in obsessive–compulsive disorder. Effects of chronic clomipramine treatment. Arch Gen Psychiatry 1988; 45: 167–172.

Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL. Serotonergic responsivity in obsessive–compulsive disorder. Effects of chronic clomipramine treatment. Arch Gen Psychiatry 1988; 45: 167–172.